UniProtKB/Swiss-Prot Q15796: Variant p.Leu449Ser

Mothers against decapentaplegic homolog 2
Gene: SMAD2
Feedback?

Variant information Variant position:

449 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Leucine (L) to Serine (S) at position 449 (L449S, p.Leu449Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and hydrophobic (L) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In LDS6; uncertain significance. Any additional useful information about the variant.

Sequence information Variant position:

449 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

467 The length of the canonical sequence.
Location on the sequence:

QTVTSTPCWIELHLNGPLQW L DKVLTQMGSPSVRCSSMS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS

Mouse                         QTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS

Rat                           QTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS

Bovine                        QTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS

Zebrafish                     QTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 467	Mothers against decapentaplegic homolog 2
Domain	274 – 467	MH2
Modified residue	458 – 458	Phosphoserine
Modified residue	460 – 460	Phosphoserine
Modified residue	464 – 464	Phosphoserine
Modified residue	465 – 465	Phosphoserine; by TGFBR1
Modified residue	467 – 467	Phosphoserine; by TGFBR1
Mutagenesis	464 – 464	S -> A. Loss of phosphorylation by TGFBR1; when associated with A-465 and A-467.
Mutagenesis	465 – 465	S -> A. No change in binding to PPM1A. Loss of phosphorylation by TGFBR1; when associated with A-464 and A-467.
Mutagenesis	465 – 465	S -> D. No change in binding to PPM1A.
Mutagenesis	467 – 467	S -> A. No change in binding to PPM1A. Loss of phosphorylation by TGFBR1; when associated with A-464 and A-465.
Mutagenesis	467 – 467	S -> D. No change in binding to PPM1A.
Helix	443 – 453

Literature citations
SMAD2 Mutations Are Associated with Arterial Aneurysms and Dissections.
Micha D.; Guo D.C.; Hilhorst-Hofstee Y.; van Kooten F.; Atmaja D.; Overwater E.; Cayami F.K.; Regalado E.S.; van Uffelen R.; Venselaar H.; Faradz S.M.; Vriend G.; Weiss M.M.; Sistermans E.A.; Maugeri A.; Milewicz D.M.; Pals G.; van Dijk F.S.;
Hum. Mutat. 36:1145-1149(2015)
Cited for: INVOLVEMENT IN LDS6; VARIANTS LDS6 ARG-388; SER-449 AND ARG-457;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.